Humanized pertussis antibodies and uses thereof
US-10035846-B2 · Jul 31, 2018 · US
Bispecific pertussis antibodies
US10538579B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10538579-B2 |
| Application number | US-201715677092-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 15, 2017 |
| Priority date | Aug 15, 2016 |
| Publication date | Jan 21, 2020 |
| Grant date | Jan 21, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates, in part, to bispecific antibodies that bind the pertussis toxin protein. The present invention further relates to the use of the bispecific antibodies for the prevention and treatment of Bordetella pertussis infections.
First claim
Opening claim text (preview).
What is claimed is: 1. A bispecific antibody that binds a pertussis toxin protein, comprising an immunoglobulin heavy chain and light chain of a humanized 1B7 antibody, wherein the immunoglobulin heavy chain derived from the humanized 1B7 antibody comprises a CDR H1 comprising an amino acid sequence of SEQ ID NO: 1, a CDR H2 comprising an amino acid sequence of SEQ ID NO:2, and a CDR H3 comprising an amino acid sequence of SEQ ID NO: 3; and the immunoglobulin light chain derived from the humanized 1B7 antibody comprises a CDR L1 comprising an amino acid sequence of SEQ ID NO: 6, a CDR L2 comprising an amino acid sequence of SEQ ID NO: 7, and a CDR L3 comprising an amino acid sequence of SEQ ID NO: 8; and an immunoglobulin heavy chain and light chain of a humanized 11E6 antibody, wherein the immunoglobulin heavy chain derived from the humanized 11E6 antibody comprises a CDR H1 comprising an amino acid sequence of SEQ ID NO: 11, a CDR H2 comprising an amino acid sequence of SEQ ID NO: 12, and a CDR H3 comprising an amino acid sequence of SEQ ID NO: 13; and the immunoglobulin light chain derived from the humanized 11E6 antibody comprises a CDR L1 comprising an amino acid sequence of SEQ ID NO: 16, a CDR L 2 comprising an amino acid sequence of SEQ ID NO: 17, and a CDR L 3 comprising an amino acid sequence of SEQ ID NO: 18, wherein the immunoglobulin heavy chain derived from the humanized 1B7 antibody comprises a mutation at T366, numbered according to the EU index as in Kabat and wherein the immunoglobulin heavy chain derived from the humanized 11E6 antibody comprises a mutation at Y407, numbered according to the EU index as in Kabat. 2. The bispecific antibody of claim 1 , wherein the immunoglobulin heavy chain derived from the humanized 1B7 antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 70% sequence identity with SEQ ID NO: 4; and the immunoglobulin light chain derived from the humanized 1B7 antibody comprises a light chain variable region comprising an amino acid sequence having at least 70% sequence identity with SEQ ID NO: 9. 3. The bispecific antibody of claim 1 , wherein the immunoglobulin heavy chain derived from the humanized 1B7 antibody comprises an amino acid sequence having at least 70% sequence identity with SEQ ID NO:5, and the immunoglobulin light chain derived from the humanized 1B7 antibody comprises an amino acid sequence having at least 70% sequence identity with SEQ ID NO: 10. 4. The bispecific antibody of claim 1 , where the mutation at T366 is T366Y. 5. The bispecific antibody of claim 1 , wherein the immunoglobulin heavy chain derived from the humanized 11E6 antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 70% sequence identity with SEQ ID NO: 14; and the immunoglobulin light chain derived from the humanized 11E6 antibody comprises a light chain variable region comprising an amino acid sequence having at least 70% sequence identity with SEQ ID NO: 19. 6. The bispecific antibody of claim 1 , wherein the immunoglobulin heavy chain derived from the humanized 11E6 antibody comprises an amino acid sequence having at least 70% sequence identity with SEQ ID NO: 15, and the immunoglobulin light chain derived from the humanized 11E6 antibody comprises an amino acid sequence having at least 70% sequence identity with SEQ ID NO: 20. 7. The bispecific antibody of claim 1 , where the mutation at Y407 is Y407T. 8. A pharmaceutical composition comprising the bispecific antibody of claim 1 , and a pharmaceutically acceptable excipient. 9. A method of treating a patient infected with Bordetella pertussis , comprising administering to the patient the bispecific antibody of claim 1 . 10. A method of preventing pertussis in a subject previously exposed to Bordetella pertussis , comprising administering to the subject the bispecific antibody of claim 1 .
Assignees
Inventors
Classifications
Complete light chain, i.e. VL + CL · CPC title
Fab or Fab' · CPC title
Antibacterial agents · CPC title
multispecific · CPC title
Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10538579B2 cover?
- The present invention relates, in part, to bispecific antibodies that bind the pertussis toxin protein. The present invention further relates to the use of the bispecific antibodies for the prevention and treatment of Bordetella pertussis infections.
- Who is the assignee on this patent?
- Univ Texas
- What technology area does this patent fall under?
- Primary CPC classification C07K16/1225. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).